FDA approves Xeris Biopharma's sNDA of Gvoke VialDx as gastro diagnostic aid

Retrieved on: 2025-03-17 21:01:24

Tags for this article:

Click the tags to see associated articles and topics

FDA approves Xeris Biopharma's sNDA of Gvoke VialDx as gastro diagnostic aid. View article details on hiswai:

Excerpt

Xeris Biopharma (XERS) Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug Admin.

Article found on: markets.businessinsider.com